2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106446
    Rentiapril 80830-42-8 99.59%
    Rentiapril is an orally active angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity.
    Rentiapril
  • HY-106447
    Losulazine 72141-57-2 98.83%
    Losulazine is an orally active antihypertensive agent. Losulazine modulates acid phosphatase, 3β-hydroxysteroid dehydrogenase, and 17β-hydroxysteroid dehydrogenase activity. Losulazine can be used for the research of hypertension.
    Losulazine
  • HY-106509
    Velaresol 77858-21-0 99.59%
    Velaresol (BW 12C) is a small molecule oxyhemoglobin stabilizer. Velaresol stabilizes hemoglobin’s oxy-conformation, shifts oxygen dissociation curves left, induces tumor hypoxia, alters radiosensitivity, protects normal tissues from radiation damage, and reduces sickled cell counts. Velaresol can be used for the research of cancer and sickle cell disease.
    Velaresol
  • HY-106538
    Cadralazine 64241-34-5 98.74%
    Cadralazine (ISF 2469) is an orally active antihypertensive agent. Cadralazine is a peripheral arteriolar vasodilator.
    Cadralazine
  • HY-106720
    Amosulalol 85320-68-9 98.69%
    Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR).
    Amosulalol
  • HY-106994
    Nebentan 403604-85-3 99.67%
    Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo.
    Nebentan
  • HY-107326
    Bunazosin 80755-51-7 98.52%
    Bunazosin is a potent and selective α1-adrenoceptor antagonist. Bunazosin can be used for antihypertensive and ocular hypotensive research.
    Bunazosin
  • HY-107335
    Aplodan 6903-79-3 99.20%
    Aplodan (Creatinol O-phosphate) is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or acute myocardial infarction .
    Aplodan
  • HY-107348
    Etofylline clofibrate 54504-70-0 99.77%
    Etofylline clofibrate has ypolipidemic and antithrombotic effect. Etofylline clofibrate has an agonistic interaction with intimal PGI2.
    Etofylline clofibrate
  • HY-107354
    Gepefrine 18840-47-6 98.09%
    Gepefrine is an orally active pressor agent and sympathomimetic agent. Gepefrine improves the early orthostatic disregulation of the arterial pressure.
    Gepefrine
  • HY-107546
    CFM 1571 hydrochloride 1215548-30-3 99.47%
    CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases.
    CFM 1571 hydrochloride
  • HY-107659
    YM-244769 hydrochloride 837424-39-2 98.09%
    YM-244769 hydrochloride is a potent, selective and orally active Na+/Ca2+ exchanger (NCX) inhibitor. YM-244769 hydrochloride preferentially inhibits NCX3 and suppresses the unidirectional outward NCX current (Ca2+ entry mode), with IC50s of 18 nM and 50 nM, respectively. YM-244769 hydrochloride efficiently protects against hypoxia/reoxygenation-induced SH-SY5Y neuronal cell damage. YM-244769 hydrochloride can also increase urine volume and urinary excretion of electrolytes in mice.
    YM-244769 hydrochloride
  • HY-108049
    GW856464 851690-21-6 99.83%
    GW856464 is an antagonist for MCHR1. GW856464 can be studied in research for cardiovascular diseases and obesity.
    GW856464
  • HY-108440
    Shz-1 326886-05-9 99.88%
    Shz-1, a small cardiogenic molecule, induces various cardiac-specific genes including sarcomeric tropomyosin in P19CL6 cells. Shz-1 induces Nkx2.5 expression in mouse. Shz-1 activates the axolotl TPM4 promoter-driven ectopic expression in C2C12 cells.
    Shz-1
  • HY-108515
    (+)-Igmesine hydrochloride 99.0%
    (+)-Igmesine hydrochloride (JO1784) is an orally active and selective σ1 receptor ligand with an IC50 of 39 nM. (+)-Igmesine hydrochloride binds σ1 receptors to activate G-proteins and modulate Ca2+ uptake. (+)-Igmesine (hydrochloride) attenuates ischaemia-induced nitric oxide synthase activity and hyperactivity. (+)-Igmesine hydrochloride can be used for the research of duodenal ulcers, gastric ulcers, and cerebral ischaemia.
    (+)-Igmesine hydrochloride
  • HY-108600
    CGP-53353 145915-60-2 98.87%
    CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients.
    CGP-53353
  • HY-109877
    Ro 22-3581 10041-06-2 99.91%
    Ro 22-3581 (4'-(Imidazol-1-yl) acetophenone) is a selective thromboxane (Tx) synthetase inhibitor.
    Ro 22-3581
  • HY-110116
    SD-2590 hydrochloride 226395-93-3 99.4%
    SD-2590 hydrochloride is a potent MMP inhibitor with IC50 values of ﹤0.1, ﹤0.1, 0.18, and 1.7 nM for MMP2, MMP13, MMP9, and MMP8, respectively. SD-2590 hydrochloride inhibits dilation of the left ventricle in rats.
    SD-2590 hydrochloride
  • HY-110183
    Angiotensin A 51833-76-2 98.13%
    Angiotensin A is a renin–angiotensin system (RAS) peptide that causes a vasoconstrictive effect dependent on AT1 receptors. Angiotensin A elicits pressor and renal vasoconstrictor responses in normotensive and hypertensive rats.
    Angiotensin A
  • HY-111447
    VAS 3947 869853-70-3 99.59%
    VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins.
    VAS 3947
Cat. No. Product Name / Synonyms Application Reactivity